Personalis (NASDAQ:PSNL) Stock Price Up 11.3% – Should You Buy?

Personalis, Inc. (NASDAQ:PSNL)’s stock price rose 11.3% during trading on Thursday . The company traded as high as $11.39 and last traded at $11.9980. Approximately 339,639 shares were traded during trading, a decline of 81% from the average daily volume of 1,800,092 shares. The stock had previously closed at $10.78.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on PSNL shares. Morgan Stanley reduced their target price on shares of Personalis from $10.00 to $9.00 and set an “equal weight” rating for the company in a research note on Tuesday, May 12th. BTIG Research cut their price target on Personalis from $13.00 to $11.00 and set a “buy” rating on the stock in a report on Monday, May 11th. Wall Street Zen raised Personalis from a “sell” rating to a “hold” rating in a research report on Saturday, May 30th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Personalis in a research report on Tuesday, April 21st. Finally, Needham & Company LLC increased their price objective on Personalis from $10.00 to $12.00 and gave the stock a “buy” rating in a report on Friday, February 27th. Five analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $11.00.

Personalis Stock Performance

The stock has a 50-day moving average of $7.23 and a 200-day moving average of $8.21. The firm has a market cap of $1.13 billion, a price-to-earnings ratio of -10.54 and a beta of 2.28.

Personalis (NASDAQ:PSNL) last announced its earnings results on Thursday, May 7th. The company reported ($0.29) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.06). Personalis had a negative net margin of 148.11% and a negative return on equity of 43.52%. The firm had revenue of $15.47 million during the quarter, compared to analyst estimates of $14.49 million. Sell-side analysts predict that Personalis, Inc. will post -1.06 EPS for the current fiscal year.

Insider Buying and Selling

In related news, CFO Aaron Tachibana sold 40,000 shares of Personalis stock in a transaction that occurred on Thursday, June 4th. The stock was sold at an average price of $12.01, for a total value of $480,400.00. Following the sale, the chief financial officer owned 198,833 shares of the company’s stock, valued at approximately $2,387,984.33. This trade represents a 16.75% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Christopher M. Hall sold 80,091 shares of Personalis stock in a transaction that occurred on Friday, May 29th. The shares were sold at an average price of $11.02, for a total value of $882,602.82. Following the completion of the sale, the chief executive officer directly owned 235,986 shares in the company, valued at approximately $2,600,565.72. This represents a 25.34% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 178,799 shares of company stock worth $2,031,692. 4.20% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in PSNL. Royal Bank of Canada increased its position in shares of Personalis by 3.2% during the 1st quarter. Royal Bank of Canada now owns 78,341 shares of the company’s stock worth $275,000 after purchasing an additional 2,395 shares during the last quarter. Dynamic Technology Lab Private Ltd increased its position in shares of Personalis by 75.6% during the 1st quarter. Dynamic Technology Lab Private Ltd now owns 76,729 shares of the company’s stock worth $269,000 after purchasing an additional 33,044 shares during the last quarter. Goldman Sachs Group Inc. increased its position in shares of Personalis by 55.7% during the 1st quarter. Goldman Sachs Group Inc. now owns 284,426 shares of the company’s stock worth $998,000 after purchasing an additional 101,706 shares during the last quarter. Focus Partners Wealth acquired a new position in shares of Personalis during the 1st quarter worth approximately $47,000. Finally, JPMorgan Chase & Co. increased its position in shares of Personalis by 505.6% during the 2nd quarter. JPMorgan Chase & Co. now owns 29,491 shares of the company’s stock worth $193,000 after purchasing an additional 24,621 shares during the last quarter. Institutional investors and hedge funds own 61.91% of the company’s stock.

About Personalis

Personalis, Inc (NASDAQ: PSNL) is a clinical‐stage genomics company that develops and markets advanced next‐generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company’s core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T‐cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno‐oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in‐depth insights into cancer, autoimmune diseases and other complex conditions.

In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development.